The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).

• Keywords
• CGM, Cardiovascular disease, Chronic kidney disease, Diabetes, Finerenone, GLP-1 RA, Guidelines, Heart failure, MASLD, NAFLD, Obesity, SGLT2 inhibitor, Teplizumab,
• MeSH
• Renal Insufficiency, Chronic * diagnosis   epidemiology   therapy   MeSH
• Diabetes Mellitus, Type 2 * drug therapy   MeSH
• Diabetes Mellitus * drug therapy   MeSH
• Cardiovascular Diseases * diagnosis   epidemiology   prevention & control   MeSH
• Blood Glucose MeSH
• Kidney MeSH
• Humans MeSH
• Obesity complications   MeSH
• Blood Glucose Self-Monitoring MeSH
• Heart Failure * complications   MeSH
• Stroke Volume MeSH
• Check Tag
• Humans MeSH
• Publication type
• Letter MeSH
• Names of Substances
• Blood Glucose MeSH

The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10-12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year's focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23-24, 2023 ( http://www.cvot.org ).

• Keywords
• Cardiovascular disease, Chronic kidney disease, Diabetes, GIP/GLP-1 receptor agonist, Heart failure, Obesity, SGLT2 inhibitor,
• MeSH
• Glucagon-Like Peptide-1 Receptor Agonists MeSH
• Renal Insufficiency, Chronic * diagnosis   drug therapy   epidemiology   MeSH
• Diabetes Mellitus, Type 2 * diagnosis   drug therapy   epidemiology   MeSH
• Hypoglycemic Agents therapeutic use   MeSH
• Cardiovascular Diseases * diagnosis   drug therapy   epidemiology   MeSH
• Blood Glucose MeSH
• Kidney MeSH
• Humans MeSH
• Blood Glucose Self-Monitoring MeSH
• Check Tag
• Humans MeSH
• Publication type
• Letter MeSH
• Names of Substances
• Glucagon-Like Peptide-1 Receptor Agonists MeSH
• Hypoglycemic Agents MeSH
• Blood Glucose MeSH